

# Antonio Uccelli

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3357363/antonio-uccelli-publications-by-year.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

224  
papers

16,387  
citations

56  
h-index

125  
g-index

251  
ext. papers

18,766  
ext. citations

6.4  
avg. IF

6.47  
L-index

#	Paper	IF	Citations
224	High or increasing serum NfL is predictive of impending multiple sclerosis relapses.. <i>Multiple Sclerosis and Related Disorders</i> , <b>2022</b> , 59, 103535	4	3
223	Neuroprotective Potential of Dendritic Cells and Sirtuins in Multiple Sclerosis.. <i>International Journal of Molecular Sciences</i> , <b>2022</b> , 23,	6.3	4
222	Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy.. <i>EBioMedicine</i> , <b>2022</b> , 80, 104042	8.8	3
221	Choroidal Thickness in Multiple Sclerosis: An Optical Coherence Tomography Study.. <i>Journal of Clinical Neurology (Korea)</i> , <b>2022</b> , 18, 334-342	1.7	0
220	Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial. <i>Lancet Neurology</i> , <b>2021</b> , 20, 917-929 <sup>24.1</sup>		9
219	COVID-19 in patients with multiple sclerosis undergoing disease-modifying treatments. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 27, 2126-2136	5	16
218	Different Susceptibility of T and B Cells to Cladribine Depends On Their Levels of Deoxycytidine Kinase Activity Linked to Activation Status. <i>Journal of NeuroImmune Pharmacology</i> , <b>2021</b> , 1	6.9	4
217	Hydroxycarboxylic Acid Receptor 2, a Pleiotropically Linked Receptor for the Multiple Sclerosis Drug, Monomethyl Fumarate. Possible Implications for the Inflammatory Response. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 655212	8.4	2
216	Signals of pseudo-starvation unveil the amino acid transporter SLC7A11 as key determinant in the control of Treg cell proliferative potential. <i>Immunity</i> , <b>2021</b> , 54, 1543-1560.e6	32.3	7
215	Intranasal delivery of mesenchymal stem cell secretome repairs the brain of Alzheimer <sup>Q</sup> mice. <i>Cell Death and Differentiation</i> , <b>2021</b> , 28, 203-218	12.7	20
214	Role of B Cells in Multiple Sclerosis and Related Disorders. <i>Annals of Neurology</i> , <b>2021</b> , 89, 13-23	9.4	38
213	Role of miRNAs shuttled by mesenchymal stem cell-derived small extracellular vesicles in modulating neuroinflammation. <i>Scientific Reports</i> , <b>2021</b> , 11, 1740	4.9	21
212	Long-Term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis. <i>Neurology</i> , <b>2021</b> ,	6.5	11
211	Neuroinflammation induces synaptic scaling through IL-1 $\beta$ -mediated activation of the transcriptional repressor REST/NRSF. <i>Cell Death and Disease</i> , <b>2021</b> , 12, 180	9.8	8
210	Therapeutic recommendations and seasonal influenza vaccine for multiple sclerosis patients in treatment with ocrelizumab: an expert consensus. <i>Journal of Neurology</i> , <b>2021</b> , 268, 1540-1543	5.5	3
209	COVID-19 Vaccination in Fragile Patients: Current Evidence and an Harmonized Transdisease Trial. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 704110	8.4	2
208	Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis. <i>Neurotherapeutics</i> , <b>2021</b> , 1	6.4	3

207	Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies. <i>EBioMedicine</i> , <b>2021</b> , 72, 103581	8.8	74
206	MiR-142-3p regulates synaptopathy-driven disease progression in multiple sclerosis. <i>Neuropathology and Applied Neurobiology</i> , <b>2021</b> ,	5.2	2
205	Mesenchymal stem cells instruct a beneficial phenotype in reactive astrocytes. <i>Glia</i> , <b>2021</b> , 69, 1204-1215g		2
204	Impact of Natural Killer (NK) Cells on Immune Reconstitution, and Their Potential as a Biomarker of Disease Activity, in Alemtuzumab-Treated Patients with Relapsing Remitting Multiple Sclerosis: An Observational Study. <i>CNS Drugs</i> , <b>2021</b> , 36, 83	6.7	1
203	Sirt6 inhibition delays the onset of experimental autoimmune encephalomyelitis by reducing dendritic cell migration. <i>Journal of Neuroinflammation</i> , <b>2020</b> , 17, 228	10.1	12
202	<sup>18</sup> F-Fluorodeoxyglucose Positron Emission Tomography Tracks the Heterogeneous Brain Susceptibility to the Hyperglycemia-Related Redox Stress. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	2
201	Aggressive multiple sclerosis: a single-centre, real-world treatment experience with autologous haematopoietic stem cell transplantation and alemtuzumab. <i>European Journal of Neurology</i> , <b>2020</b> , 27, 2047-2055	6	8
200	CD56bright Natural Killer Cells: A Possible Biomarker of Different Treatments in Multiple Sclerosis. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	13
199	Aggressive multiple sclerosis (2): Treatment. <i>Multiple Sclerosis Journal</i> , <b>2020</b> , 1352458520924595	5	6
198	Impact of treatment on cellular immunophenotype in MS: A cross-sectional study. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2020</b> , 7,	9.1	9
197	Degree of microstructural changes within T1-SE versus T1-GE hypointense lesions in multiple sclerosis: relevance for the definition of "black holes". <i>European Radiology</i> , <b>2020</b> , 30, 3843-3851	8	2
196	Fingolimod and Dimethyl-Fumarate-Derived Lymphopenia is not Associated with Short-Term Treatment Response and Risk of Infections in a Real-Life MS Population. <i>CNS Drugs</i> , <b>2020</b> , 34, 425-432	6.7	15
195	A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosis. <i>Neurology</i> , <b>2020</b> , 95, e1027-e1040	6.5	11
194	Ghost spasticity in multiple sclerosis. <i>Journal of Electromyography and Kinesiology</i> , <b>2020</b> , 51, 102408	2.5	1
193	Ocrelizumab does not impair B- and T-cell responses to primary VZV infection in a patient with MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2020</b> , 7,	9.1	5
192	Effects of aging on finger movements in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , <b>2020</b> , 37, 101449	4	2
191	A Single Nucleotide ADA Genetic Variant Is Associated to Central Inflammation and Clinical Presentation in MS: Implications for Cladribine Treatment. <i>Genes</i> , <b>2020</b> , 11,	4.2	1
190	Corneal epithelial dendritic cells in patients with multiple sclerosis: An in vivo confocal microscopy study. <i>Journal of Clinical Neuroscience</i> , <b>2020</b> , 81, 139-143	2.2	4

189	Neurological Complications and Noninvasive Multimodal Neuromonitoring in Critically Ill Mechanically Ventilated COVID-19 Patients. <i>Frontiers in Neurology</i> , <b>2020</b> , 11, 602114	4.1	20
188	X-ray Phase Contrast Tomography Serves Preclinical Investigation of Neurodegenerative Diseases. <i>Frontiers in Neuroscience</i> , <b>2020</b> , 14, 584161	5.1	3
187	Tailoring B cell depletion therapy in MS according to memory B cell monitoring. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2020</b> , 7,	9.1	21
186	COVID-19-related and not related Guillain-Barré syndromes share the same management pitfalls during lock down: The experience of Liguria region in Italy. <i>Journal of the Neurological Sciences</i> , <b>2020</b> , 418, 117114	3.2	19
185	Effect of vitamin D supplementation on N-glycan branching and cellular immunophenotypes in MS. <i>Annals of Clinical and Translational Neurology</i> , <b>2020</b> , 7, 1628-1641	5.3	1
184	Assessing upper limb function in multiple sclerosis using an engineered glove. <i>European Journal of Neurology</i> , <b>2020</b> , 27, 2561-2567	6	1
183	Ecological impact of isolated cognitive relapses in MS. <i>Multiple Sclerosis Journal</i> , <b>2020</b> , 26, 114-117	5	7
182	Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience. <i>Multiple Sclerosis Journal</i> , <b>2020</b> , 26, 1519-1531	5	19
181	COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?. <i>Multiple Sclerosis and Related Disorders</i> , <b>2020</b> , 42, 102120	4	106
180	IFN $\beta$ enhances mesenchymal stromal (Stem) cells immunomodulatory function through STAT1-3 activation and mTOR-associated promotion of glucose metabolism. <i>Cell Death and Disease</i> , <b>2019</b> , 10, 85	9.8	19
179	MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis. <i>Trials</i> , <b>2019</b> , 20, 263	2.8	41
178	Could arterial spin labelling perfusion imaging uncover the invisible in N-methyl-d-aspartate receptor encephalitis?. <i>European Journal of Neurology</i> , <b>2019</b> , 26, e86-e87	6	2
177	Different MRI patterns in MS worsening after stopping fingolimod. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2019</b> , 6, e566	9.1	13
176	Defining the role of NG2-expressing cells in experimental models of multiple sclerosis. A biofunctional analysis of the neurovascular unit in wild type and NG2 null mice. <i>PLoS ONE</i> , <b>2019</b> , 14, e0213508	2.7	19
175	Fulminant Hepatitis Associated With Echovirus 25 During Treatment With Ocrelizumab for Multiple Sclerosis. <i>JAMA Neurology</i> , <b>2019</b> , 76, 866-867	17.2	21
174	CSF oligoclonal bands and normal appearing white matter periventricular damage in patients with clinically isolated syndrome suggestive of MS. <i>Multiple Sclerosis and Related Disorders</i> , <b>2019</b> , 31, 93-96	4	4
173	Autoantibody Diagnostics in Neuroimmunology: Experience From the 2018 Italian Neuroimmunology Association External Quality Assessment Program. <i>Frontiers in Neurology</i> , <b>2019</b> , 10, 1385	4.1	13
172	Detrimental and protective action of microglial extracellular vesicles on myelin lesions: astrocyte involvement in remyelination failure. <i>Acta Neuropathologica</i> , <b>2019</b> , 138, 987-1012	14.3	67

171	Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial. <i>Lancet Neurology, The</i> , <b>2019</b> , 18, 845-856	24.1	56
170	Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis and Related Disorders</i> , <b>2019</b> , 36, 101430	4	14
169	Pediatric optic neuritis and anti MOG antibodies: a cohort of Italian patients. <i>Multiple Sclerosis and Related Disorders</i> , <b>2019</b> , 39, 101917	4	6
168	Relationship between retinal inner nuclear layer, age, and disease activity in progressive MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2019</b> , 6,	9.1	15
167	The Italian multiple sclerosis register. <i>Neurological Sciences</i> , <b>2019</b> , 40, 155-165	3.5	42
166	Tocilizumab in MOG-antibody spectrum disorder: a case report. <i>Multiple Sclerosis and Related Disorders</i> , <b>2019</b> , 27, 312-314	4	15
165	Exploring Alzheimer@ disease mouse brain through X-ray phase contrast tomography: From the cell to the organ. <i>NeuroImage</i> , <b>2019</b> , 184, 490-495	7.9	33
164	Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks. <i>Neurology</i> , <b>2018</b> , 90, e823-e831	6.5	54
163	Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks. <i>Neurology</i> , <b>2018</b> , 90, e832-e839	6.5	48
162	Overexpression of sphingosine-1-phosphate receptors on reactive astrocytes drives neuropathology of multiple sclerosis rebound after fingolimod discontinuation. <i>Multiple Sclerosis Journal</i> , <b>2018</b> , 24, 1133-1137	5	26
161	Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. <i>Lancet, The</i> , <b>2018</b> , 391, 1263-1273	40	422
160	Composite MRI measures and short-term disability in patients with clinically isolated syndrome suggestive of MS. <i>Multiple Sclerosis Journal</i> , <b>2018</b> , 24, 623-631	5	7
159	Environmental modifiable risk factors for multiple sclerosis: Report from the 2016ECTRIMS focused workshop. <i>Multiple Sclerosis Journal</i> , <b>2018</b> , 24, 590-603	5	58
158	No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study. <i>Journal of Neurology</i> , <b>2018</b> , 265, 2851-2860	5.5	24
157	Serum sickness (Like Reaction) in a patient treated with alemtuzumab for multiple sclerosis: A case report. <i>Multiple Sclerosis and Related Disorders</i> , <b>2018</b> , 26, 52-54	4	6
156	Quantitative 3D investigation of Neuronal network in mouse spinal cord model. <i>Scientific Reports</i> , <b>2017</b> , 7, 41054	4.9	29
155	Autologous hematopoietic stem cell transplantation in multiple sclerosis: A meta-analysis. <i>Neurology</i> , <b>2017</b> , 88, 2115-2122	6.5	93
154	In vitro VLA-4 blockade results in an impaired NK cell-mediated immune surveillance against melanoma. <i>Immunology Letters</i> , <b>2017</b> , 181, 109-115	4.1	10

153	Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study). <i>Journal of Neurology</i> , <b>2017</b> , 264, 2436-2449	5.5	35
152	Teriflunomide treatment reduces B cells in patients with MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2017</b> , 4, e403	9.1	21
151	X-Ray Phase Contrast Tomography Reveals Early Vascular Alterations and Neuronal Loss in a Multiple Sclerosis Model. <i>Scientific Reports</i> , <b>2017</b> , 7, 5890	4.9	47
150	Dramatic rebounds of MS during pregnancy following fingolimod withdrawal. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2017</b> , 4, e377	9.1	35
149	Immunometabolic profiling of T cells from patients with relapsing-remitting multiple sclerosis reveals an impairment in glycolysis and mitochondrial respiration. <i>Metabolism: Clinical and Experimental</i> , <b>2017</b> , 77, 39-46	12.7	37
148	Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy. <i>Neurological Sciences</i> , <b>2017</b> , 38, 53-59	3.5	22
147	IFN- $\gamma$ orchestrates mesenchymal stem cell plasticity through the signal transducer and activator of transcription 1 and 3 and mammalian target of rapamycin pathways. <i>Journal of Allergy and Clinical Immunology</i> , <b>2017</b> , 139, 1667-1676	11.5	31
146	Cell-based therapeutic strategies for multiple sclerosis. <i>Brain</i> , <b>2017</b> , 140, 2776-2796	11.2	102
145	The state of multiple sclerosis: current insight into the patient/health care provider relationship, treatment challenges, and satisfaction. <i>Patient Preference and Adherence</i> , <b>2017</b> , 11, 33-45	2.4	51
144	Human Mesenchymal Stem Cells Impact Th17 and Th1 Responses Through a Prostaglandin E2 and Myeloid-Dependent Mechanism. <i>Stem Cells Translational Medicine</i> , <b>2016</b> , 5, 1506-1514	6.9	53
143	Characterization of mouse spinal cord vascular network by means of synchrotron radiation X-ray phase contrast tomography. <i>Physica Medica</i> , <b>2016</b> , 32, 1779-1784	2.7	14
142	Dysregulation of regulatory CD56(bright) NK cells/T cells interactions in multiple sclerosis. <i>Journal of Autoimmunity</i> , <b>2016</b> , 72, 8-18	15.5	58
141	Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study. <i>Journal of Neurology</i> , <b>2016</b> , 263, 1727-35	5.5	35
140	Sirt6 regulates dendritic cell differentiation, maturation, and function. <i>Aging</i> , <b>2016</b> , 8, 34-49	5.6	23
139	Regulatory Functions of Natural Killer Cells in Multiple Sclerosis. <i>Frontiers in Immunology</i> , <b>2016</b> , 7, 606	8.4	58
138	Two Years Follow up of Domain Specific Cognitive Training in Relapsing Remitting Multiple Sclerosis: A Randomized Clinical Trial. <i>Frontiers in Behavioral Neuroscience</i> , <b>2016</b> , 10, 28	3.5	14
137	NG2, a common denominator for neuroinflammation, blood-brain barrier alteration, and oligodendrocyte precursor response in EAE, plays a role in dendritic cell activation. <i>Acta Neuropathologica</i> , <b>2016</b> , 132, 23-42	14.3	15
136	Low intensity lympho-ablative regimen followed by autologous hematopoietic stem cell transplantation in severe forms of multiple sclerosis: A MRI-based clinical study. <i>Multiple Sclerosis Journal</i> , <b>2015</b> , 21, 1423-30	5	39



135	Cingulum bundle alterations underlie subjective fatigue in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2015</b> , 21, 442-7	5	27
134	Fumarates modulate microglia activation through a novel HCAR2 signaling pathway and rescue synaptic dysregulation in inflamed CNS. <i>Acta Neuropathologica</i> , <b>2015</b> , 130, 279-95	14.3	120
133	Mesenchymal stem cells for the treatment of neurological diseases: Immunoregulation beyond neuroprotection. <i>Immunology Letters</i> , <b>2015</b> , 168, 183-90	4.1	48
132	Mesenchymal stromal cells and immunity: Introductory overview. <i>Immunology Letters</i> , <b>2015</b> , 168, 127-8	4.1	8
131	Effect of radial shock wave therapy on pain and muscle hypertonia: a double-blind study in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2015</b> , 21, 622-9	5	26
130	Human mesenchymal stem cells target adhesion molecules and receptors involved in T cell extravasation. <i>Stem Cell Research and Therapy</i> , <b>2015</b> , 6, 245	8.3	15
129	The immunomodulatory function of mesenchymal stem cells: mode of action and pathways. <i>Annals of the New York Academy of Sciences</i> , <b>2015</b> , 1351, 114-26	6.5	123
128	Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. <i>Multiple Sclerosis Journal</i> , <b>2015</b> , 21, 1013-24	5	181
127	Can we switch microglia phenotype to foster neuroprotection? Focus on multiple sclerosis. <i>Immunology</i> , <b>2014</b> , 141, 328-39	7.8	56
126	Monomethyl fumarate inhibits the NFkB pathway and pro-inflammatory cytokine expression in microglia through HCA2 signaling via the AMPK/Sirt axis. <i>Journal of Neuroimmunology</i> , <b>2014</b> , 275, 167-168	3.5	2
125	Selective impairments of motor sequence learning in multiple sclerosis patients with minimal disability. <i>Brain Research</i> , <b>2014</b> , 1585, 91-8	3.7	12
124	Acute desipramine restores presynaptic cortical defects in murine experimental autoimmune encephalomyelitis by suppressing central CCL5 overproduction. <i>British Journal of Pharmacology</i> , <b>2014</b> , 171, 2457-67	8.6	16
123	Clinical baseline factors predict response to natalizumab: their usefulness in patient selection. <i>BMC Neurology</i> , <b>2014</b> , 14, 103	3.1	9
122	Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial. <i>BMC Neurology</i> , <b>2014</b> , 14, 65	3.1	43
121	A RCT Comparing Specific Intensive Cognitive Training to Aspecific Psychological Intervention in RRMS: The SMICT Study. <i>Frontiers in Neurology</i> , <b>2014</b> , 5, 278	4.1	20
120	Isolated cognitive relapses in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2014</b> , 85, 1035-7	5.5	77
119	Mesenchymal stem cells exert a remarkable regenerative effect requiring minimal CNS integration: commentary on: "Mesenchymal stem cells protect CNS neurons against glutamate excitotoxicity by inhibiting glutamate receptor expression and function" by Voulgari-Kokota et al. <i>Experimental Neurology</i> , <b>2013</b> , 247, 292-5	5.7	11
118	Fingolimod modulates peripheral effector and regulatory T cells in MS patients. <i>Journal of NeuroImmune Pharmacology</i> , <b>2013</b> , 8, 1106-13	6.9	58

117	Intrathecal soluble HLA-E correlates with disease activity in patients with multiple sclerosis and may cooperate with soluble HLA-G in the resolution of neuroinflammation. <i>Journal of NeuroImmune Pharmacology</i> , <b>2013</b> , 8, 944-55	6.9	26
116	CCL5-glutamate interaction in central nervous system: Early and acute presynaptic defects in EAE mice. <i>Neuropharmacology</i> , <b>2013</b> , 75, 337-46	5.5	23
115	Mesenchymal stem cells as treatment for MS - progress to date. <i>Multiple Sclerosis Journal</i> , <b>2013</b> , 19, 515-9		50
114	Towards clinical application of mesenchymal stem cells for treatment of neurological diseases of the central nervous system. <i>Journal of NeuroImmune Pharmacology</i> , <b>2013</b> , 8, 1062-76	6.9	41
113	Reward responsiveness and fatigue in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2013</b> , 19, 233-40	5	30
112	Early switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruption. <i>Multiple Sclerosis Journal</i> , <b>2013</b> , 19, 1236-7	5	29
111	Quantitative assessment of finger motor impairment in multiple sclerosis. <i>PLoS ONE</i> , <b>2013</b> , 8, e65225	3.7	35
110	Nicotinamide phosphoribosyltransferase (NAMPT) inhibitors as therapeutics: rationales, controversies, clinical experience. <i>Current Drug Targets</i> , <b>2013</b> , 14, 637-43	3	42
109	Mesenchymal Stem Cells for the Treatment of Multiple Sclerosis <b>2013</b> , 433-455		4
108	Neurorepair with mesenchymal stem cells: hope or hype?. <i>Lancet Neurology</i> , <b>2012</b> , 11, 123-5	24.1	11
107	T-cell trafficking in the central nervous system. <i>Immunological Reviews</i> , <b>2012</b> , 248, 216-27	11.3	126
106	The therapeutic effect of mesenchymal stem cell transplantation in experimental autoimmune encephalomyelitis is mediated by peripheral and central mechanisms. <i>Stem Cell Research and Therapy</i> , <b>2012</b> , 3, 3	8.3	62
105	Mesenchymal stem cells shape microglia effector functions through the release of CX3CL1. <i>Stem Cells</i> , <b>2012</b> , 30, 2044-53	5.8	98
104	Patient adherence to and tolerability of self-administered interferon $\beta$ 1a using an electronic autoinjection device: a multicentre, open-label, phase IV study. <i>BMC Neurology</i> , <b>2012</b> , 12, 7	3.1	42
103	Urinary JCV-DNA testing during natalizumab treatment may increase accuracy of PML risk stratification. <i>Journal of NeuroImmune Pharmacology</i> , <b>2012</b> , 7, 665-72	6.9	28
102	Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience. <i>Multiple Sclerosis Journal</i> , <b>2012</b> , 18, 835-42	5	95
101	Anti-glutamic acid decarboxylase limbic encephalitis without epilepsy evolving into dementia with cerebellar ataxia. <i>Archives of Neurology</i> , <b>2012</b> , 69, 1064-6		12
100	Th17 cells in multiple sclerosis express higher levels of JAK2, which increases their surface expression of IFN- $\beta$ 2. <i>Journal of Immunology</i> , <b>2012</b> , 188, 1011-8	5.3	18



99	Blood-brain barrier alterations in the cerebral cortex in experimental autoimmune encephalomyelitis. <i>Journal of Neuropathology and Experimental Neurology</i> , <b>2012</b> , 71, 840-54	3.1	49
98	Intravenous mesenchymal stem cells improve survival and motor function in experimental amyotrophic lateral sclerosis. <i>Molecular Medicine</i> , <b>2012</b> , 18, 794-804	6.2	109
97	Regulation of human mesenchymal stem cell functions by an autocrine loop involving NAD <sup>+</sup> release and P2Y <sub>11</sub> -mediated signaling. <i>Stem Cells and Development</i> , <b>2011</b> , 20, 1183-98	4.4	48
96	Neuroprotective features of mesenchymal stem cells. <i>Best Practice and Research in Clinical Haematology</i> , <b>2011</b> , 24, 59-64	4.2	165
95	Mesenchymal stem cells for multiple sclerosis: does neural differentiation really matter?. <i>Current Stem Cell Research and Therapy</i> , <b>2011</b> , 6, 69-72	3.6	18
94	Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases. <i>Lancet Neurology</i> , <b>2011</b> , 10, 649-56	24.1	231
93	Association of melanoma and natalizumab therapy in the Italian MS population: a second case report. <i>Neurological Sciences</i> , <b>2011</b> , 32, 181-2	3.5	19
92	Recommendations for the management of urinary disorders in multiple sclerosis: a consensus of the Italian Multiple Sclerosis Study Group. <i>Neurological Sciences</i> , <b>2011</b> , 32, 1223-31	3.5	33
91	Can we kill an extra bird with the same stone?. <i>Inflammatory Bowel Diseases</i> , <b>2011</b> , 17, E124-5	4.5	1
90	A case of thyroiditis during natalizumab therapy for multiple sclerosis. <i>Journal of Endocrinological Investigation</i> , <b>2011</b> , 34, 408-9	5.2	2
89	Mesenchymal stem cells impair in vivo T-cell priming by dendritic cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2011</b> , 108, 17384-9	11.5	208
88	Primary varicella zoster infection associated with fingolimod treatment. <i>Neurology</i> , <b>2011</b> , 76, 1023-4	6.5	28
87	Alterations of glutamate release in the spinal cord of mice with experimental autoimmune encephalomyelitis. <i>Journal of Neurochemistry</i> , <b>2010</b> , 115, 343-52	6	10
86	Systemic administration of mesenchymal stem cells increases neuron survival after global cerebral ischemia in vivo (2VO). <i>Neural Plasticity</i> , <b>2010</b> , 2010, 534925	3.3	22
85	Surrogate endpoints for EDSS worsening in multiple sclerosis. A meta-analytic approach. <i>Neurology</i> , <b>2010</b> , 75, 302-9	6.5	92
84	The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group. <i>Multiple Sclerosis Journal</i> , <b>2010</b> , 16, 503-10	5	185
83	Immuno-therapeutic potential of haematopoietic and mesenchymal stem cell transplantation in MS. <i>Results and Problems in Cell Differentiation</i> , <b>2010</b> , 51, 237-57	1.4	11
82	Stem cell transplantation in multiple sclerosis. <i>Current Opinion in Neurology</i> , <b>2010</b> , 23, 218-25	7.1	39

81	Contact with the bone marrow microenvironment readdresses the fate of transplanted hematopoietic stem cells. <i>Experimental Hematology</i> , <b>2010</b> , 38, 968-77	3.1	14
80	Interferon- $\beta$ -dependent inhibition of B cell activation by bone marrow-derived mesenchymal stem cells in a murine model of systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>2010</b> , 62, 2776-86		136
79	Why should mesenchymal stem cells (MSCs) cure autoimmune diseases?. <i>Current Opinion in Immunology</i> , <b>2010</b> , 22, 768-74	7.8	115
78	Catastrophic NAD <sup>+</sup> depletion in activated T lymphocytes through Nampt inhibition reduces demyelination and disability in EAE. <i>PLoS ONE</i> , <b>2009</b> , 4, e7897	3.7	119
77	Economic evaluation of treating clinically isolated syndrome and subsequent multiple sclerosis with interferon beta-1b. <i>Neurological Sciences</i> , <b>2009</b> , 30, 21-31	3.5	27
76	Autologous haematopoietic stem-cell transplantation in multiple sclerosis: benefits and risks. <i>Neurological Sciences</i> , <b>2009</b> , 30 Suppl 2, S175-7	3.5	11
75	Retinal nerve fibre layer measurements and optic nerve head analysis in multiple sclerosis patients. <i>Eye</i> , <b>2009</b> , 23, 407-12	4.4	19
74	Multipotent mesenchymal stromal cells for autoimmune diseases: teaching new dogs old tricks. <i>Bone Marrow Transplantation</i> , <b>2009</b> , 43, 821-8	4.4	84
73	C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. <i>Nature Immunology</i> , <b>2009</b> , 10, 514-23	19.1	853
72	Neuroprotective mesenchymal stem cells are endowed with a potent antioxidant effect in vivo. <i>Journal of Neurochemistry</i> , <b>2009</b> , 110, 1674-84	6	149
71	Reciprocal interactions between human mesenchymal stem cells and gammadelta T cells or invariant natural killer T cells. <i>Stem Cells</i> , <b>2009</b> , 27, 693-702	5.8	129
70	Catastrophic NAD <sup>+</sup> Depletion in Activated T Lymphocytes through Nampt Inhibition Reduces Demyelination and Disability in EAE.. <i>Blood</i> , <b>2009</b> , 114, 4732-4732	2.2	
69	Mesenchymal stem cells in health and disease. <i>Nature Reviews Immunology</i> , <b>2008</b> , 8, 726-36	36.5	2469
68	Immunotherapy for neurological diseases. <i>Clinical Immunology</i> , <b>2008</b> , 128, 294-305	9	42
67	Investigation of paroxysmal dystonia in a patient with multiple sclerosis: a transcranial magnetic stimulation study. <i>Clinical Neurophysiology</i> , <b>2008</b> , 119, 63-70	4.3	14
66	Adult stem cells for spinal cord injury: what types and how do they work?. <i>Cytotherapy</i> , <b>2008</b> , 10, 541-2	4.8	6
65	Is there a role for mesenchymal stem cells in autoimmune diseases?. <i>Autoimmunity</i> , <b>2008</b> , 41, 592-5	3	37
64	Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study. <i>Multiple Sclerosis Journal</i> , <b>2008</b> , 14, 1225-33	5	58

63	Multipotent mesenchymal stromal cells from amniotic fluid: solid perspectives for clinical application. <i>Haematologica</i> , <b>2008</b> , 93, 339-46	6.6	137
62	Neuropathological Advances in Multiple Sclerosis <b>2007</b> , 3-9		
61	Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis. <i>Annals of Neurology</i> , <b>2007</b> , 61, 219-27	9.4	381
60	The molecular signature of therapeutic mesenchymal stem cells exposes the architecture of the hematopoietic stem cell niche synapse. <i>BMC Genomics</i> , <b>2007</b> , 8, 65	4.5	53
59	Antibodies against Epstein-Barr virus and herpesvirus type 6 are associated with the early phases of multiple sclerosis. <i>Journal of Neuroimmunology</i> , <b>2007</b> , 192, 184-5	3.5	14
58	Autologous stem cell transplantation for severe autoimmune diseases: a 10-year experience. <i>Annals of the New York Academy of Sciences</i> , <b>2007</b> , 1110, 455-64	6.5	22
57	Human mesenchymal stem cells promote survival of T cells in a quiescent state. <i>Stem Cells</i> , <b>2007</b> , 25, 1753-60	5.8	208
56	Relapses after treatment with rituximab in a patient with multiple sclerosis and anti myelin-associated glycoprotein polyneuropathy. <i>Archives of Neurology</i> , <b>2007</b> , 64, 1531-3		27
55	Mesenchymal stem cells: a new strategy for immunosuppression?. <i>Trends in Immunology</i> , <b>2007</b> , 28, 219-264.4	4.4	369
54	Immunomodulatory properties of mesenchymal stem cells: a review based on an interdisciplinary meeting held at the Kennedy Institute of Rheumatology Division, London, UK, 31 October 2005. <i>Arthritis Research and Therapy</i> , <b>2007</b> , 9, 301	5.7	137
53	Mechanisms of the adaptive immune response inside the central nervous system during inflammatory and autoimmune diseases <b>2006</b> , 111, 555-66		23
52	Immunoregulatory function of mesenchymal stem cells. <i>European Journal of Immunology</i> , <b>2006</b> , 36, 2566-73	6.3	436
51	Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. <i>Human Molecular Genetics</i> , <b>2006</b> , 15, 2813-24	5.6	246
50	Stem cells in inflammatory demyelinating disorders: a dual role for immunosuppression and neuroprotection. <i>Expert Opinion on Biological Therapy</i> , <b>2006</b> , 6, 17-22	5.4	51
49	Human mesenchymal stem cells modulate B-cell functions. <i>Blood</i> , <b>2006</b> , 107, 367-72	2.2	1372
48	Costs and quality of life of multiple sclerosis in Italy. <i>European Journal of Health Economics</i> , <b>2006</b> , 7 Suppl 2, S45-54	3.6	50
47	Unveiling the enigma of the CNS as a B-cell fostering environment. <i>Trends in Immunology</i> , <b>2005</b> , 26, 254-264.4	4.4	68
46	Phenotypic and functional characterisation of CCR7+ and CCR7- CD4+ memory T cells homing to the joints in juvenile idiopathic arthritis. <i>Arthritis Research</i> , <b>2005</b> , 7, R256-67		41

45	Conventional perimetry, short-wavelength automated perimetry, frequency-doubling technology, and visual evoked potentials in the assessment of patients with multiple sclerosis. <i>European Journal of Ophthalmology</i> , <b>2005</b> , 15, 730-8	1.9	22
44	Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. <i>Blood</i> , <b>2005</b> , 106, 1755-61	2.2	1165
43	B-cell differentiation in the CNS of patients with multiple sclerosis. <i>Autoimmunity Reviews</i> , <b>2005</b> , 4, 549-54.6	5.6	50
42	Immunological patterns identifying disease course and evolution in multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , <b>2005</b> , 165, 192-200	3.5	36
41	Intense immunosuppression followed by autologous stem cell transplantation in severe multiple sclerosis. <i>Neurological Sciences</i> , <b>2005</b> , 26 Suppl 4, S200-3	3.5	15
40	Autologous stem cell transplantation as rescue therapy in malignant forms of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2005</b> , 11, 367-71	5	62
39	The prevalence of pain in multiple sclerosis: a multicenter cross-sectional study. <i>Neurology</i> , <b>2004</b> , 63, 919-21	6.5	221
38	Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2004</b> , 101, 11064-9	11.5	280
37	Alpha-lipoic acid is effective in prevention and treatment of experimental autoimmune encephalomyelitis. <i>Journal of Neuroimmunology</i> , <b>2004</b> , 148, 146-53	3.5	101
36	Biological markers of the inflammatory phase of multiple sclerosis. <i>Neurological Sciences</i> , <b>2003</b> , 24 Suppl 5, S271-4	3.5	20
35	Phenotypic and functional analysis of T cells homing into the CSF of subjects with inflammatory diseases of the CNS. <i>Journal of Leukocyte Biology</i> , <b>2003</b> , 73, 584-90	6.5	140
34	Vaccination with amyloid-beta peptide induces autoimmune encephalomyelitis in C57/BL6 mice. <i>Brain</i> , <b>2003</b> , 126, 285-91	11.2	99
33	EAE in the common marmoset <i>Callithrix jacchus</i> . <i>International MS Journal</i> , <b>2003</b> , 10, 6-12		11
32	Central and peripheral nervous system complications following allogeneic bone marrow transplantation. <i>European Journal of Neurology</i> , <b>2001</b> , 8, 77-80	6	31
31	Characterization of the response to myelin basic protein in a non human primate model for multiple sclerosis. <i>European Journal of Immunology</i> , <b>2001</b> , 31, 474-479	6.1	7
30	Delivery to the central nervous system of a nonreplicative herpes simplex type 1 vector engineered with the interleukin 4 gene protects rhesus monkeys from hyperacute autoimmune encephalomyelitis. <i>Human Gene Therapy</i> , <b>2001</b> , 12, 905-20	4.8	52
29	Guillain-Barré syndrome after reactivation of varicella-zoster virus. <i>New England Journal of Medicine</i> , <b>2001</b> , 344, 65-6	59.2	8
28	Demyelination and axonal damage in a non-human primate model of multiple sclerosis. <i>Journal of the Neurological Sciences</i> , <b>2001</b> , 184, 41-9	3.2	68

27	Characterization of the response to myelin basic protein in a non human primate model for multiple sclerosis. <i>European Journal of Immunology</i> , <b>2001</b> , 31, 474-9	6.1	1
26	Restricted immune responses lead to CNS demyelination and axonal damage. <i>Journal of Neuroimmunology</i> , <b>2000</b> , 107, 178-83	3.5	9
25	Myelin basic protein intramolecular spreading without disease progression in a patient with multiple sclerosis. <i>Journal of Neuroimmunology</i> , <b>2000</b> , 110, 240-3	3.5	10
24	Myelin/oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis in common marmosets: the encephalitogenic T cell epitope pMOG24-36 is presented by a monomorphic MHC class II molecule. <i>Journal of Immunology</i> , <b>2000</b> , 165, 1093-101	5.3	112
23	Gabapentin is effective in treating nocturnal painful spasms in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2000</b> , 6, 192-3	5	40
22	Low-dose gabapentin combined with either lamotrigine or carbamazepine can be useful therapies for trigeminal neuralgia in multiple sclerosis. <i>European Neurology</i> , <b>2000</b> , 44, 45-8	2.1	85
21	Gabapentin is effective in treating nocturnal painful spasms in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2000</b> , 6, 192-193	5	2
20	Multiple sclerosis and non-communicating syringomyelia: a casual association or linked diseases?. <i>Acta Neurologica Scandinavica</i> , <b>1999</b> , 100, 270-3	3.8	5
19	A major influence of the T cell receptor repertoire as compared to antigen processing-presentation in the selection of myelin basic protein epitopes in multiple sclerosis. <i>Journal of Neuroimmunology</i> , <b>1999</b> , 96, 241-4	3.5	1
18	Animal Models of Demyelination of the Central Nervous System <b>1999</b> , 233-245		1
17	Experimental autoimmune encephalomyelitis in the common marmoset <i>Callithrix jacchus</i> <b>1999</b> , 79-84		
16	A restricted T cell response to myelin basic protein (MBP) is stable in multiple sclerosis (MS) patients. <i>Clinical and Experimental Immunology</i> , <b>1998</b> , 111, 186-92	6.2	15
15	An open-label trial of gabapentin treatment of paroxysmal symptoms in multiple sclerosis patients. <i>Neurology</i> , <b>1998</b> , 51, 609-11	6.5	100
14	Effect of copolymer-1 on serial gadolinium-enhanced MRI in relapsing remitting multiple sclerosis. <i>Neurology</i> , <b>1998</b> , 50, 1127-33	6.5	88
13	Differential display analysis of murine encephalitogenic mRNA. <i>International Immunology</i> , <b>1998</b> , 10, 1819-23	4.9	5
12	Characterization of the TCRB chain repertoire in the New World monkey <i>Callithrix jacchus</i> . <i>Journal of Immunology</i> , <b>1997</b> , 158, 1201-7	5.3	34
11	Local-clonal expansion of infiltrating T lymphocytes in chronic encephalitis of Rasmussen. <i>Journal of Immunology</i> , <b>1997</b> , 158, 1428-37	5.3	65
10	Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1995</b> , 92, 3601-5	11.5	156

9	17p11.2 duplication is a common finding in sporadic cases of Charcot-Marie-Tooth type 1. <i>European Neurology</i> , <b>1994</b> , 34, 135-9	2.1	15
8	Intravenous immunoglobulin, plasmalymphocytapheresis and azathioprine in chronic progressive multiple sclerosis. <i>Italian Journal of Neurological Sciences</i> , <b>1994</b> , 15, 51-3		5
7	Hereditary motor and sensory neuropathy with myelin outfolding: clinical, genetic and neuropathological study of three cases. <i>Journal of the Neurological Sciences</i> , <b>1994</b> , 122, 20-7	3.2	16
6	Induction of experimental autoimmune encephalomyelitis in rats and immune response to myelin basic protein in lipid-bound form. <i>Journal of the Neurological Sciences</i> , <b>1993</b> , 119, 91-8	3.2	13
5	Circulating lymphocyte subsets after total lymphoid irradiation in chronic progressive multiple sclerosis. <i>Annals of the New York Academy of Sciences</i> , <b>1993</b> , 677, 458-61	6.5	
4	Charcot-Marie-Tooth (CMT) 1a duplication at 17p11.2 in Italian families. <i>Journal of Medical Genetics</i> , <b>1992</b> , 29, 492-3	5.8	20
3	Interindividual variability of cranioencephalic relationships as predicted by CT. <i>Journal of Computer Assisted Tomography</i> , <b>1991</b> , 15, 647-54	2.2	
2	Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies		6
1	Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 135245852210972	5	1